CASR and secondary hyperparathyroidism: In the GPCR field, cinacalcet, an allosteric enhancer of the calcium-sensing receptor (CaR), has recently been approved for the treatment of secondary hyperparathyroidism in dialysis patients suffering from chronic kidney disease [11].